Don’t Worry About Rare Covishield Side Effects, Expert Says
Dr. Raman Gangakhedkar reassured that Covishield’s rare side effect, Thrombosis Thrombocytopenia Syndrome (TTS), affects only seven to eight per million vaccinated, with risks decreasing after subsequent doses. The Serum Institute of India (SII), the world’s largest vaccine producer, played a crucial role in global vaccine distribution. AstraZeneca acknowledged the rare risk of TTS in UK court documents but reaffirmed its commitment to vaccine safety and stringent regulatory standards. Experts urge the public not to panic or rely on misinformation, as scientists continue to monitor and study vaccine effects. Global health agencies support Covishield’s safety and effectiveness in preventing severe COVID-19 cases. AstraZeneca remains committed to transparency and public trust in vaccination efforts.
Don’t Worry About Rare Covishield Side Effects, Expert Says
Experts reassure the public that rare Covishield side effects, like Thrombosis Thrombocytopenia Syndrome (TTS), are extremely uncommon. Scientists continue monitoring vaccine safety, emphasizing that its benefits far outweigh the risks.
Covishield: Minimal Risk, Significant Benefits
Dr. Raman Gangakhedkar recently addressed concerns about the rare side effects associated with the Covishield vaccine, particularly Thrombosis Thrombocytopenia Syndrome (TTS). He highlighted that this condition affects only about seven to eight individuals per million vaccinated. While the risk is present, it remains minimal compared to the significant benefits provided to millions of recipients. The likelihood of these side effects is highest within the first two to three months after vaccination, with the risk being greatest after the first dose, decreasing with the second, and lowest after the third.
Serum Institute of India: A Global Vaccine Leader
Covishield is manufactured by the Serum Institute of India (SII), the world’s largest vaccine producer. The company played a crucial role in India’s vaccination drive, ensuring widespread access to the COVID-19 vaccine.
SII has a long-standing reputation for producing affordable and high-quality vaccines, supplying doses to both domestic and international markets. During the pandemic, it rapidly scaled up production to meet global demand, providing millions of doses to low- and middle-income countries through the COVAX initiative. The institute’s commitment to vaccine research, innovation, and large-scale manufacturing has positioned it as a key player in global public health.
AstraZeneca Acknowledges Rare Clot Risk but Stands by Vaccine Safety
In UK court documents, AstraZeneca, which partnered with the University of Oxford for the vaccine’s development, acknowledged the rare risk of Thrombosis with Thrombocytopenia Syndrome (TTS) linked to its COVID-19 vaccine. However, the company reaffirmed its dedication to patient safety, emphasizing that regulatory authorities have established stringent safety standards for all medications, including vaccines. Expressing sympathy for those affected, AstraZeneca remains committed to maintaining public confidence in its vaccine.
The pharmaceutical giant stressed that the occurrence of TTS remains extremely rare and that the benefits of vaccination continue to far outweigh the risks. It reiterated that global regulatory bodies, including the World Health Organization (WHO) and the European Medicines Agency (EMA), have reviewed extensive data and continue to support the vaccine’s use based on its effectiveness in preventing severe illness and hospitalization due to COVID-19.
AstraZeneca also pointed out that all vaccines undergo rigorous clinical trials before approval and are continuously monitored for safety once they are in widespread use. The company pledged to work closely with health authorities worldwide to address any concerns and ensure transparency in its findings. Despite ongoing legal proceedings, AstraZeneca maintains that Covishield and its counterpart Vaxzevria have played a vital role in global vaccination efforts, helping to save millions of lives.
Experts Urge Public to Stay Informed, Not Panic
Renowned epidemiologist Dr. Samiran Panda reassured the public that there is no need for panic or reliance on internet searches for information. He emphasized that scientists are actively investigating the situation and will provide clear guidance as more insights emerge.
Dr. Panda highlighted that misinformation and fear-driven searches can lead to unnecessary anxiety, often amplifying concerns beyond what scientific evidence supports. He encouraged individuals to rely on credible sources such as public health agencies, government advisories, and medical professionals for accurate updates.
He further explained that while rare side effects like Thrombosis Thrombocytopenia Syndrome (TTS) are being studied, the overall benefits of the Covishield vaccine far outweigh the risks. Vaccines have played a crucial role in reducing severe illness and death during the pandemic, and ongoing surveillance ensures that any potential concerns are swiftly addressed.
Public health experts continue to monitor vaccine safety data worldwide, ensuring transparency and timely updates to maintain trust in vaccination efforts.
Check out TimesWordle.com for all the latest news
Related articles:
Covishield Vaccine: 7 Risks in Context, Explained by Science
5 thoughts on “Don’t Worry About Rare Covishield Side Effects, Expert Says”